Eagle Pharmaceuticals Inc (EGRX) — Net Asset Quality Index
Eagle Pharmaceuticals Inc (EGRX) has a Net Asset Quality Index of 62.3% as of June 2023. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $404.82 Million minus total liabilities of $152.78 Million yields net assets of $252.04 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Eagle Pharmaceuticals Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Eagle Pharmaceuticals Inc Net Asset Quality Index Over Time (2012–2022)
This chart shows how Eagle Pharmaceuticals Inc's Net Asset Quality Index has evolved across 11 annual periods from 2012 to 2022. As of June 2023, the index stands at 62.3%, representing net assets of $252.04 Million against total assets of $404.82 Million USD. Explore EGRX cash generation efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Eagle Pharmaceuticals Inc (2012–2022)
The table below presents the year-by-year Net Asset Quality Index for Eagle Pharmaceuticals Inc from 2012 to 2022, covering 11 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Eagle Pharmaceuticals Inc market capitalisation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2022 | 57.5% | $233.56 Million | $406.16 Million | $172.60 Million | ▼ -12.0 pp |
| 2021 | 69.5% | $176.45 Million | $253.73 Million | $77.28 Million | ▼ -3.9 pp |
| 2020 | 73.5% | $186.01 Million | $253.19 Million | $67.18 Million | ▲ +3.1 pp |
| 2019 | 70.4% | $179.17 Million | $254.55 Million | $75.38 Million | ▲ +3.0 pp |
| 2018 | 67.4% | $160.76 Million | $238.60 Million | $77.84 Million | ▲ +1.0 pp |
| 2017 | 66.3% | $179.14 Million | $270.06 Million | $90.92 Million | ▼ -4.5 pp |
| 2016 | 70.8% | $151.23 Million | $213.57 Million | $62.34 Million | ▼ -1.7 pp |
| 2015 | 72.5% | $90.34 Million | $124.61 Million | $34.26 Million | ▲ +10.5 pp |
| 2014 | 62.0% | $33.10 Million | $53.41 Million | $20.32 Million | ▲ +50.6 pp |
| 2013 | 11.3% | $2.05 Million | $18.10 Million | $16.05 Million | ▲ +139.5 pp |
| 2012 | -128.2% | $-12.10 Million | $9.44 Million | $21.54 Million | — |